Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia


Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. British Journal of Haematology [Internet]. 2016;175(1):77 - 86.


The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM. © 2016 John Wiley & Sons Ltd


Cited By :3Export Date: 18 February 2017References: Avet-Loiseau, H., Garand, R., Lode, L., Harousseau, J.L., Bataille, R., Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants (2003) Blood, 101, pp. 1570-1571;Baehring, J.M., Hochberg, E.P., Raje, N., Ulrickson, M., Hochberg, F.H., Neurological manifestations of Waldenstrom macroglobulinemia (2008) Nature Clinical Practice Neurology, 4, pp. 547-556; Banwait, R., Aljawai, Y., Cappuccio, J., McDiarmid, S., Morgan, E.A., Leblebjian, H., Roccaro, A.M., Ghobrial, I.M., Extramedullary Waldenstrom macroglobulinemia (2015) American Journal of Hematology, 90, pp. 100-104; Berentsen, S., Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom's macroglobulinemia (2009) Clinical Lymphoma Myeloma, 9, pp. 110-112; Braggio, E., Fonseca, R., Genomic abnormalities of Waldenstrom macroglobulinemia and related low-grade B-cell lymphomas (2013) Clinical Lymphoma Myeloma and Leukemia, 13, pp. 198-201; Brambilla, F., Lavatelli, F., Valentini, V., Di Silvestre, D., Obici, L., Mauri, P., Merlini, G., Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis (2012) Amyloid, 19, pp. 11-13; Castillo, J.J., Olszewski, A.J., Cronin, A.M., Hunter, Z.R., Treon, S.P., Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database (2014) Blood, 123, pp. 3999-4000; Castillo, J.J., Olszewski, A.J., Kanan, S., Meid, K., Hunter, Z.R., Treon, S.P., Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database (2015) British Journal of Haematology, 169, pp. 81-89; Castillo, J.J., D'Sa, S., Lunn, M.P., Minnema, M.C., Tedeschi, A., Lansigan, F., Palomba, M.L., Treon, S.P., Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study (2016) British Journal of Haematology, 172, pp. 709-715; Ciccarelli, B.T., Patterson, C.J., Hunter, Z.R., Hanzis, C., Ioakimidis, L., Manning, R., Yang, G., Treon, S.P., Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstrom's macroglobulinemia (2011) Clinical Lymphoma Myeloma and Leukemia, 11, pp. 160-163; Fernandez de Larrea, C., Verga, L., Morbini, P., Klersy, C., Lavatelli, F., Foli, A., Obici, L., Merlini, G., A practical approach to the diagnosis of systemic amyloidoses (2015) Blood, 125, pp. 2239-2244; Feyler, S., O'Connor, S.J., Rawstron, A.C., Subash, C., Ross, F.M., Pratt, G., Drayson, M.T., Owen, R.G., IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14) (2008) British Journal of Haematology, 140, pp. 547-551; Ghobrial, I.M., Fonseca, R., Greipp, P.R., Blood, E., Rue, M., Vesole, D.H., Gertz, M.A., Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study (2004) Cancer, 101, pp. 2593-2598; Gnemmi, V., Leleu, X., Provot, F., Moulonguet, F., Buob, D., Cast nephropathy and light-chain deposition disease in Waldenstrom macroglobulinemia (2012) American Journal of Kidney Diseases, 60, pp. 487-491; Hivert, B., Caron, C., Petit, S., Charpy, C., Fankam-Siaka, C., Lecocq, S., Zawadzki, C., Morel, P., Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia (2012) Blood, 120, pp. 3214-3221; Hunter, Z.R., Manning, R.J., Hanzis, C., Ciccarelli, B.T., Ioakimidis, L., Patterson, C.J., Lewicki, M.C., Treon, S.P., IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia (2010) Haematologica, 95, pp. 470-475; Hunter, Z.R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R.J., Treon, S.P., The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis (2014) Blood, 123, pp. 1637-1646; Jimenez, C., Sebastian, E., Chillon, M.C., Giraldo, P., Mariano Hernandez, J., Escalante, F., Gonzalez-Lopez, T.J., Garcia-Sanz, R., MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia (2013) Leukemia, 27, pp. 1722-1728; Konoplev, S., Medeiros, L.J., Bueso-Ramos, C.E., Jorgensen, J.L., Lin, P., Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (2005) American Journal of Clinical Pathology, 124, pp. 414-420; Kyle, R.A., Treon, S.P., Alexanian, R., Barlogie, B., Bjorkholm, M., Dhodapkar, M., Lister, T.A., Leblond, V., Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia (2003) Seminars in Oncology, 30, pp. 116-120; Leleu, X., Soumerai, J., Roccaro, A., Hatjiharissi, E., Hunter, Z.R., Manning, R., Ciccarelli, B.T., Treon, S.P., Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs (2009) Journal of Clinical Oncology, 27, pp. 250-255; Leleu, X., Xie, W., Bagshaw, M., Banwait, R., Leduc, R., Roper, N., Weller, E., Ghobrial, I.M., The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia (2011) Clinical Cancer Research, 17, pp. 3013-3018; Levine, T., Pestronk, A., Florence, J., Al-Lozi, M.T., Lopate, G., Miller, T., Ramneantu, I., Choksi, R., Peripheral neuropathies in Waldenstrom's macroglobulinaemia (2006) Journal of Neurology, Neurosurgery and Psychiatry, 77, pp. 224-228; Menke, M.N., Treon, S.P., Hyperviscosity syndrome (2007) Clinical Malignant Hematology, pp. 937-941. , In, (eds by, M. Sekeres, M. Kalaycio, &, B. Bolwell, McGraw-Hill, New York; Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M.A., Dhodapkar, M.V., McCoy, J., Crowley, J., Merlini, G., International prognostic scoring system for Waldenstrom macroglobulinemia (2009) Blood, 113, pp. 4163-4170; Morice, W.G., Chen, D., Kurtin, P.J., Hanson, C.A., McPhail, E.D., Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia (2009) Modern Pathology, 22, pp. 807-816; Nguyen-Khac, F., Lambert, J., Chapiro, E., Grelier, A., Mould, S., Barin, C., Daudignon, A., Leblondon, V., Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia (2013) Haematologica, 98, pp. 649-654; Ocio, E.M., Schop, R.F., Gonzalez, B., Van Wier, S.A., Hernandez-Rivas, J.M., Gutierrez, N.C., Garcia-Sanz, R., Fonseca, R., 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis (2007) British Journal of Haematology, 136, pp. 80-86; Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Dimopoulos, M.A., Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia (2003) Seminars in Oncology, 30, pp. 110-115; Owen, R.G., Bynoe, A.G., Varghese, A., de Tute, R.M., Rawstron, A.C., Heterogeneity of histological transformation events in Waldenstrom's macroglobulinemia (WM) and related disorders (2011) Clinical Lymphoma Myeloma and Leukemia, 11, pp. 176-179; Paiva, B., Montes, M.C., Garcia-Sanz, R., Ocio, E.M., Alonso, J., de Las Heras, N., Escalante, F., San Miguel, J.F., Multiparameter flow cytometry for the identification of the Waldenstrom's clone in IgM-MGUS and Waldenstrom's Macroglobulinemia: new criteria for differential diagnosis and risk stratification (2014) Leukemia, 28, pp. 166-173; Poulain, S., Dervite, I., Leleu, X., Fernandes, J., Stalnikiewicz, L., Moreau, A.S., Coiteux, V., Morel, P., Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenstrom's macroglobulinemia: association with FcgammaRIIa polymorphism (2006) Leukemia, 20, pp. 1179-1181; Poulain, S., Roumier, C., Decambron, A., Renneville, A., Herbaux, C., Bertrand, E., Tricot, S., Leleu, X., MYD88 L265P mutation in Waldenstrom macroglobulinemia (2013) Blood, 121, pp. 4504-4511; Poulain, S., Roumier, C., Venet-Caillault, A., Figeac, M., Herbaux, C., Marot, G., Doye, E., Leleu, X., Genomic landscape of CXCR4 mutations in Waldenstrom's Macroglobulinemia (2016) Clinical Cancer Research, 22, pp. 1480-1488; Roccaro, A.M., Sacco, A., Jimenez, C., Maiso, P., Moschetta, M., Mishima, Y., Aljawai, Y., Ghobrial, I.M., C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma (2014) Blood, 123, pp. 4120-4131; Schmidt, J., Federmann, B., Schindler, N., Steinhilber, J., Bonzheim, I., Fend, F., Quintanilla-Martinez, L., MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity (2015) British Journal of Haematology, 169, pp. 795-803; Schonland, S.O., Hegenbart, U., Bochtler, T., Mangatter, A., Hansberg, M., Ho, A.D., Lohse, P., Rocken, C., Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients (2012) Blood, 119, pp. 488-493; Schop, R.F., Fonseca, R., Genetics and cytogenetics of Waldenstrom's macroglobulinemia (2003) Seminars in Oncology, 30, pp. 142-145; Simon, L., Fitsiori, A., Lemal, R., Dupuis, J., Carpentier, B., Boudin, L., Corby, A., Fornecker, L.M., Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO) (2015) Haematologica, 100, pp. 1587-1594; Sipe, J.D., Benson, M.D., Buxbaum, J.N., Ikeda, S., Merlini, G., Saraiva, M.J., Westermark, P., Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis (2014) Amyloid, 21, pp. 221-224; Steingrimsson, V., Lund, S.H., Turesson, I., Goldin, L.R., Bjorkholm, M., Landgren, O., Kristinsson, S.Y., Population-based study on the impact of the familial form of Waldenstrom macroglobulinemia on overall survival (2015) Blood, 125, pp. 2174-2175; Stone, M.J., Waldenstrom's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia (2009) Clin Lymphoma Myeloma, 9, pp. 97-99; Stone, M.J., Bogen, S.A., Evidence-based focused review of management of hyperviscosity syndrome (2012) Blood, 119, pp. 2205-2208; Swerdlow, S.H., Berger, F., Pileri, S.A., Harris, N.L., Jaffe, E.S., Stein, H., Lymphoplasmacytic lymphoma (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, pp. 194-195. , In, (eds., S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, &, J.W. Vardiman, IARC, Lyon, France; Terrier, B., Jaccard, A., Harousseau, J.L., Delarue, R., Tournilhac, O., Hunault-Berger, M., Hamidou, M., Fakhouri, F., The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients (2008) Medicine (Baltimore), 87, pp. 99-109; Treon, S.P., How I treat Waldenstrom macroglobulinemia (2009) Blood, 114, pp. 2375-2385; Treon, S.P., How I treat Waldenstrom macroglobulinemia (2015) Blood, 126, pp. 721-732; Treon, S.P., Branagan, A.R., Hunter, Z., Santos, D., Tournhilac, O., Anderson, K.C., Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia (2004) Annals of Oncology, 15, pp. 1481-1483; Treon, S.P., Tripsas, C., Hanzis, C., Ioakimidis, L., Patterson, C.J., Manning, R.J., Sheehy, P., Hunter, Z.R., Familial disease predisposition impacts treatment outcome in patients with Waldenstrom macroglobulinemia (2012) Clinical Lymphoma Myeloma and Leukemia, 12, pp. 433-437; Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Hunter, Z.R., MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia (2012) New England Journal of Medicine, 367, pp. 826-833; Treon, S.P., Tripsas, C.K., Ciccarelli, B.T., Manning, R.J., Patterson, C.J., Sheehy, P., Hunter, Z.R., Patients with Waldenstrom macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration (2013) Clinical Lymphoma Myeloma and Leukemia, 13, pp. 241-243; Treon, S.P., Cao, Y., Xu, L., Yang, G., Liu, X., Hunter, Z.R., Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia (2014) Blood, 123, pp. 2791-2796; Treon, S.P., Xu, L., Hunter, Z., MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia (2015) New England Journal of Medicine, 373, pp. 584-586; Treon, S.P., Tripsas, C.K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K.V., Advani, R.H., Ibrutinib in previously treated Waldenstrom's macroglobulinemia (2015) New England Journal of Medicine, 372, pp. 1430-1440; Vlam, L., Piepers, S., Sutedja, N.A., Jacobs, B.C., Tio-Gillen, A.P., Stam, M., Franssen, H., van den Berg, L.H., Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study (2015) Journal of Neurology, 262, pp. 666-673; Vos, J.M., Manning, R.R., Meid, K., Gustine, J., Patterson, C.J., Brodsky, P., Kanan, S., Castillo, J.J., Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS (2015) Blood, 126, p. 3926; Vrana, J.A., Gamez, J.D., Madden, B.J., Theis, J.D., Bergen, H.R., 3rd, Dogan, A., Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens (2009) Blood, 114, pp. 4957-4959; Xu, L., Hunter, Z.R., Yang, G., Cao, Y., Liu, X., Manning, R., Tripsas, C., Treon, S.P., Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance (2014) Leukemia, 28, pp. 1698-1704